PHILADELPHIA – September 03, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug ...

HONOLULU - October 29, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV™ (guanfacine) Extended Release Tablets, at a ...

Takeda Pharmaceutical Co has agreed to pay $1.85 million to settle claims by consumers that its predecessor Shire PLC delayed the launch of a generic version of its ADHD drug Intuniv through an ...

LONDON (Reuters) - U.S. regulators approved Shire's extended-release hyperactivity drug Intuniv and the product is expected to be available in U.S. pharmacies in November, the company said on Thursday ...

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents First once-daily nonstimulant to be ...

Shire Receives Approvable Letter From FDA for Intuniv (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 21, 2007 -- ...

The class action suit, filed in Massachusetts federal court, alleges that Shire and New Jersey-based Actavis conspired to delay the release of a cheaper, generic version of Intuniv. A new class action ...

TAIPEI, June 3, 2015 -- TWi Pharmaceuticals, Inc. ("TWi") (stock ticker: 4180.TT) today announced that it has received final approval from the United States Food and Drug Administration (FDA) on its ...

Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...

Shire Plc. SHPG announced that its Japanese partner Shionogi & Co., Ltd submitted a new drug application (NDA) for the manufacture and marketing of Intuniv (guanfacine hydrochloride extended release) ...

PHILADELPHIA British drug maker Shire will present data on two attention deficit hyperactivity disorder treatments in New Orleans starting this week, Shire said. The company said it would present data ...

NEW ORLEANS British drug maker Shire presented late-stage clinical study data at a psychiatric meeting Friday indicating that administration of one of its drugs along with stimulants provided symptom ...